Table 4.
Multivariate analysis for biochemical progression-free survival
| Parameter |
HR (95%CI) |
p |
HR (95%CI) |
p |
HR (95%CI) |
p |
|---|---|---|---|---|---|---|
| PSA |
|
0.19 |
|
0.24 |
|
0.22 |
| ≤ 15 ng/ml |
1.0 |
|
1.0 |
|
1.0 |
|
| >15 ng/ml |
0.55 (0.23–1.33) |
|
0.59 (0.25–1.42) |
|
0.57 (0.24–1.38) |
|
| Gleason |
|
0.91 |
|
0.90 |
|
0.74 |
| < 7 |
1.0 |
|
1.0 |
|
1.0 |
|
| ≥ 7 |
1.04 (0.48–2.27) |
|
0.95 (0.44–2.07) |
|
1.14 (0.53–2.45) |
|
| Age |
|
0.16 |
|
0.17 |
|
0.16 |
| ≤61 years |
1.0 |
|
1.0 |
|
1.0 |
|
| >61 years |
1.76 (0.80–3.88) |
|
1.73 (0.79–3.79) |
|
1.76 (0.80–3.85) |
|
| HIF1α |
|
0.01 |
|
|
|
|
| ≤ 50% |
1.0 |
|
|
|
|
|
| >50% |
0.37 (0.17–0.82 |
|
|
|
|
|
| EGFR |
|
|
|
0.04 |
|
|
| negative |
|
|
1.0 |
|
|
|
| Weak or strong |
|
|
(1.03–7.43) |
|
|
|
| VEGF-A |
|
|
|
|
|
0.96 |
| low |
|
|
|
|
1.0 |
|
| high | 0.97 (0.39–2.42) |
PSA prostatic-specific antigen.